JP2008525460A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008525460A5 JP2008525460A5 JP2007548380A JP2007548380A JP2008525460A5 JP 2008525460 A5 JP2008525460 A5 JP 2008525460A5 JP 2007548380 A JP2007548380 A JP 2007548380A JP 2007548380 A JP2007548380 A JP 2007548380A JP 2008525460 A5 JP2008525460 A5 JP 2008525460A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- composition
- nucleotides
- interfering rna
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002773 nucleotide Substances 0.000 claims 48
- 125000003729 nucleotide group Chemical group 0.000 claims 48
- 230000000692 anti-sense effect Effects 0.000 claims 32
- 239000000203 mixture Substances 0.000 claims 32
- 108020004999 messenger RNA Proteins 0.000 claims 26
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 22
- 230000002452 interceptive effect Effects 0.000 claims 22
- 230000000295 complement effect Effects 0.000 claims 12
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 claims 10
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 claims 10
- 230000004962 physiological condition Effects 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 4
- 208000030533 eye disease Diseases 0.000 claims 4
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 2
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 208000022873 Ocular disease Diseases 0.000 claims 2
- 230000002238 attenuated effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000029663 wound healing Effects 0.000 claims 2
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims 1
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63870504P | 2004-12-23 | 2004-12-23 | |
| US60/638,705 | 2004-12-23 | ||
| PCT/US2005/046064 WO2006069037A1 (en) | 2004-12-23 | 2005-12-19 | Rnai inhibition of ctgf for treatment of ocular disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012029499A Division JP2012097119A (ja) | 2004-12-23 | 2012-02-14 | 眼の障害を処置するためのＣＴＧＦのＲＮＡｉ阻害 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008525460A JP2008525460A (ja) | 2008-07-17 |
| JP2008525460A5 true JP2008525460A5 (enExample) | 2009-02-12 |
| JP5095414B2 JP5095414B2 (ja) | 2012-12-12 |
Family
ID=36218404
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007548380A Expired - Fee Related JP5095414B2 (ja) | 2004-12-23 | 2005-12-19 | 眼の障害を処置するためのＣＴＧＦのＲＮＡｉ阻害 |
| JP2012029499A Withdrawn JP2012097119A (ja) | 2004-12-23 | 2012-02-14 | 眼の障害を処置するためのＣＴＧＦのＲＮＡｉ阻害 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012029499A Withdrawn JP2012097119A (ja) | 2004-12-23 | 2012-02-14 | 眼の障害を処置するためのＣＴＧＦのＲＮＡｉ阻害 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US7622454B2 (enExample) |
| EP (2) | EP1827503A1 (enExample) |
| JP (2) | JP5095414B2 (enExample) |
| KR (1) | KR20070091337A (enExample) |
| CN (1) | CN101160138B (enExample) |
| AR (1) | AR052172A1 (enExample) |
| AU (1) | AU2005319279B2 (enExample) |
| BR (1) | BRPI0516377A (enExample) |
| CA (1) | CA2591611A1 (enExample) |
| MX (1) | MX2007007654A (enExample) |
| TW (1) | TWI386225B (enExample) |
| WO (1) | WO2006069037A1 (enExample) |
| ZA (1) | ZA200704932B (enExample) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2598234A1 (en) | 2005-03-11 | 2006-09-21 | Alcon, Inc. | Rnai-mediated inhibition of frizzled related protein-1 for treatment of glaucoma |
| US20060275797A1 (en) * | 2005-03-21 | 2006-12-07 | Alcon Manufacturing, Ltd. | Use of agents which inhibit connective tissue growth factor (CTGF) binding and signaling via the TrkA/p75NTR receptor complex for the prevention and treatment of CTGF-mediated ocular disorders |
| AU2008308784B2 (en) * | 2007-10-01 | 2013-07-18 | Arrowhead Research Corporation | Self complementary AAV-mediated delivery of interfering RNA molecules to treat or prevent ocular disorders |
| US7973019B1 (en) | 2007-10-03 | 2011-07-05 | Alcon Research, Ltd. | Transferrin/transferrin receptor-mediated siRNA delivery |
| US20090131358A1 (en) * | 2007-11-15 | 2009-05-21 | Alcon Research, Ltd. | LOW DENSITY LIPOPROTEIN RECEPTOR-MEDIATED siRNA DELIVERY |
| TW200932274A (en) | 2007-12-18 | 2009-08-01 | Alcon Res Ltd | Interfering RNA delivery system and uses thereof |
| US8446125B2 (en) | 2008-06-20 | 2013-05-21 | Superior Communications, Inc. | Vehicle power charger |
| US8946172B2 (en) | 2008-08-25 | 2015-02-03 | Excaliard Pharmaceuticals, Inc. | Method for reducing scarring during wound healing using antisense compounds directed to CTGF |
| EP2334319B1 (en) * | 2008-08-25 | 2017-12-06 | Excaliard Pharmaceuticals, Inc. | Method for reducing scarring during wound healing using antisense compounds directed to ctgf |
| CN107083386A (zh) * | 2008-08-25 | 2017-08-22 | 埃克斯雷德制药有限公司 | 阻止结缔组织生长因子的反义核苷酸及其用途 |
| EP2342340A1 (en) | 2008-09-22 | 2011-07-13 | Rxi Pharmaceuticals Corporation | Rna interference in skin indications |
| WO2010090762A1 (en) | 2009-02-04 | 2010-08-12 | Rxi Pharmaceuticals Corporation | Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
| JP2012520683A (ja) * | 2009-03-19 | 2012-09-10 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いた結合組織増殖因子（ＣＴＧＦ）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| CA2794189C (en) | 2010-03-24 | 2022-01-11 | Rxi Pharmaceuticals Corporation | Rna interference in dermal and fibrotic indications |
| US9095504B2 (en) | 2010-03-24 | 2015-08-04 | Rxi Pharmaceuticals Corporation | RNA interference in ocular indications |
| KR101249041B1 (ko) * | 2010-04-28 | 2013-03-29 | 포항공과대학교 산학협력단 | 결합조직 성장인자를 이용한 약학적 조성물 |
| EP2582365B1 (en) * | 2010-06-16 | 2019-03-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions for stimulating reepithelialisation during wound healing |
| CN103328633B (zh) | 2010-10-22 | 2018-07-10 | 成均馆大学校产学协力团 | 诱导rna干扰的核酸分子及其用途 |
| JP2014505666A (ja) | 2010-11-18 | 2014-03-06 | ザ ジェネラル ホスピタル コーポレイション | 癌治療のための降圧剤の組成物および使用 |
| DK2670411T3 (da) * | 2011-02-02 | 2019-05-13 | Excaliard Pharmaceuticals Inc | Antisense-forbindelser rettet mod bindevævsvækstfaktor (CTGF) til anvendelse i en fremgangsmåde til behandling af keloider eller hypertrofiske ar |
| CN102727513B (zh) * | 2011-04-15 | 2014-07-09 | 百奥迈科生物技术有限公司 | 靶向于组织因子基因的小核酸及其用途 |
| WO2012161677A1 (en) | 2011-05-20 | 2012-11-29 | Alcon Research, Ltd. | TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED siRNA DELIVERY |
| US8802839B2 (en) * | 2011-07-15 | 2014-08-12 | Fibrogen, Inc. | Connective tissue growth factor antisense oligonucleotides |
| US20130178421A1 (en) | 2012-01-06 | 2013-07-11 | Alcon Research, Ltd. | Interfering rna delivery system and uses thereof |
| JP5906327B2 (ja) | 2012-01-18 | 2016-04-20 | バイオニア コーポレーションＢｉｏｎｅｅｒ Ｃｏｒｐｏｒａｔｉｏｎ | 磁性ナノ粒子−ＳＡＭｉＲＮＡ複合体およびその製造方法 |
| CN108148838B (zh) * | 2012-05-22 | 2026-07-31 | 奥利克斯医药有限公司 | 具有细胞内穿透能力的诱导rna干扰的核酸分子及用途 |
| US9695421B2 (en) | 2013-07-05 | 2017-07-04 | Bioneer Corporation | Dengue virus-specific siRNA, double helix oligo-RNA structure comprising siRNA, and composition for suppressing proliferation of dengue virus comprising RNA structure |
| RU2656154C2 (ru) * | 2013-07-05 | 2018-05-31 | Байонир Корпорейшн | СВЯЗАННАЯ С РЕСПИРАТОРНЫМ ЗАБОЛЕВАНИЕМ ГЕН-СПЕЦИФИЧЕСКАЯ миРНК, ДВУСПИРАЛЬНАЯ КОНСТРУКЦИЯ ОЛИГО-РНК, СОДЕРЖАЩАЯ миРНК, И СОДЕРЖАЩАЯ ЕЕ КОМПОЗИЦИЯ ДЛЯ ПРЕДУПРЕЖДЕНИЯ ИЛИ ЛЕЧЕНИЯ РЕСПИРАТОРНОГО ЗАБОЛЕВАНИЯ |
| CA2917299C (en) | 2013-07-05 | 2020-07-21 | Bioneer Corporation | Improved nanoparticle type oligonucleotide structure having high efficiency and method for preparing same |
| WO2015085113A1 (en) * | 2013-12-04 | 2015-06-11 | Rxi Pharmaceuticals Corporation | Methods for treatment of wound healing utilizing chemically modified oligonucleotides |
| WO2015152693A2 (ko) | 2014-04-04 | 2015-10-08 | (주)바이오니아 | 신규 이중 나선 올리고 rna 및 이를 포함하는 섬유증 또는 호흡기 질환의 예방 또는 치료용 약학조성물 |
| CA2947270A1 (en) | 2014-04-28 | 2015-11-05 | Rxi Pharmaceuticals Corporation | Methods for treating cancer using nucleic acids targeting mdm2 or mycn |
| US10314690B1 (en) * | 2014-05-12 | 2019-06-11 | Gholam A. Peyman | Method of corneal transplantation or corneal inlay implantation with cross-linking |
| US11648261B2 (en) | 2014-05-12 | 2023-05-16 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
| US11565023B2 (en) | 2014-05-12 | 2023-01-31 | Gholam A. Peyman | Method of corneal transplantation or corneal inlay implantation with cross-linking |
| US10881503B2 (en) | 2014-05-12 | 2021-01-05 | Gholam A. Peyman | Method of corneal transplantation or corneal inlay implantation with cross-linking |
| US11338059B2 (en) | 2014-05-12 | 2022-05-24 | Gholam A. Peyman | Method of corneal and scleral inlay crosslinking and preservation |
| US11045352B2 (en) | 2014-05-12 | 2021-06-29 | Gholam A. Peyman | Methods for treatment of dry eye and other acute or chronic inflammatory processes |
| US10925889B2 (en) | 2014-05-12 | 2021-02-23 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
| US10583221B2 (en) | 2014-05-12 | 2020-03-10 | Gholam A. Peyman | Method of corneal transplantation or corneal inlay implantation with cross-linking |
| US11666777B2 (en) | 2014-05-12 | 2023-06-06 | Gholam A. Peyman | Photodynamic therapy technique for preventing damage to the fovea of the eye or another body portion of a patient |
| US12396889B2 (en) | 2014-05-12 | 2025-08-26 | Gholam A. Peyman | Lamellar corneal autologous or homologous graft in refractive surgery |
| WO2016179329A1 (en) | 2015-05-04 | 2016-11-10 | The Regents Of The University Of Colorado, A Body Corporate | Wireless power transfer |
| JP7027311B2 (ja) | 2015-11-16 | 2022-03-01 | オリックス ファーマシューティカルズ，インコーポレーテッド | ＭｙＤ８８又はＴＬＲ３を標的とするＲＮＡ複合体を使用した加齢黄斑変性の治療 |
| EP3389720A1 (en) | 2015-12-18 | 2018-10-24 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
| KR102825945B1 (ko) | 2016-02-02 | 2025-06-30 | 올릭스 주식회사 | Angpt2 및 pdgfb를 표적화하는 rna 복합체를 사용하는 혈관신생 관련 질환의 치료 |
| WO2017134525A1 (en) | 2016-02-02 | 2017-08-10 | Olix Pharmaceuticals, Inc. | TREATMENT OF ATOPIC DERMATITIS AND ASTHMA USING RNA COMPLEXES THAT TARGET lL4Rα, TRPA1, OR F2RL1 |
| JP7049262B2 (ja) | 2016-04-11 | 2022-04-06 | オリックス ファーマシューティカルズ，インコーポレーテッド | 結合組織成長因子を標的とするｒｎａ複合体を用いた特発性肺胞線維症の治療 |
| KR101916652B1 (ko) | 2016-06-29 | 2018-11-08 | 올릭스 주식회사 | 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도 |
| WO2018146557A2 (en) | 2017-02-10 | 2018-08-16 | Dong Ki Lee | Long double-stranded rna for rna interference |
| US10363833B2 (en) * | 2017-03-15 | 2019-07-30 | Ford Global Technologies, Llc | Inductive charging active suspension |
| KR20190037166A (ko) * | 2017-09-28 | 2019-04-05 | 올릭스 주식회사 | 결합 조직 성장 인자를 표적으로 하는 rna 복합체를 함유하는 노인성 황반변성의 예방 또는 치료용 약학 조성물 |
| CN112512532B (zh) * | 2018-07-31 | 2024-11-08 | 雷莫内克斯生物制药有限公司 | 用于抑制ctgf表达的组合物 |
| US11707518B2 (en) | 2019-04-28 | 2023-07-25 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
| US12226478B2 (en) | 2019-04-28 | 2025-02-18 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
| CN110144350A (zh) * | 2019-05-15 | 2019-08-20 | 基诺泰康生物科技(北京)有限公司 | 一种特异性抑制CTGF基因表达的siRNA及其在抑制癜痕形成中的应用 |
| KR102757180B1 (ko) | 2019-11-22 | 2025-01-21 | (주)바이오니아 | Ctgf 유전자 특이적 이중가닥 올리고뉴클레오티드 및 이를 포함하는 섬유증 관련 질환 및 호흡기 관련 질환 예방 및 치료용 조성물 |
| KR102421750B1 (ko) * | 2020-05-26 | 2022-07-19 | 올릭스 주식회사 | MyD88을 표적으로 하는 RNAi 제제 및 이의 용도 |
| CN114807127A (zh) * | 2021-01-19 | 2022-07-29 | 陈璞 | 用于结缔组织生长因子的小干扰rna及其应用 |
| WO2023239756A1 (en) | 2022-06-07 | 2023-12-14 | Generation Bio Co. | Lipid nanoparticle compositions and uses thereof |
| WO2025147949A1 (zh) * | 2024-01-11 | 2025-07-17 | 广州瑞风生物科技有限公司 | 基因编辑系统及其应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5408040A (en) | 1991-08-30 | 1995-04-18 | University Of South Florida | Connective tissue growth factor(CTGF) |
| US5770209A (en) * | 1991-08-30 | 1998-06-23 | University Of South Florida | Acceleration of wound healing using connective tissue growth factor |
| US7384634B2 (en) * | 1991-08-30 | 2008-06-10 | University Of South Florida | Connective tissue growth factor |
| WO1994001550A1 (en) * | 1992-07-02 | 1994-01-20 | Hybridon, Inc. | Self-stabilized oligonucleotides as therapeutic agents |
| US5734039A (en) * | 1994-09-15 | 1998-03-31 | Thomas Jefferson University | Antisense oligonucleotides targeting cooperating oncogenes |
| US7041548B1 (en) * | 1996-07-16 | 2006-05-09 | Micron Technology, Inc. | Methods of forming a gate stack that is void of silicon clusters within a metallic silicide film thereof |
| US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US6348329B1 (en) * | 1998-11-06 | 2002-02-19 | Fibrogen, Inc. | Nucleic acids encoding rat connective tissue growth factor (CTGF) and methods of use |
| US7115390B1 (en) * | 1998-12-14 | 2006-10-03 | Fibrogen, Inc. | Connective tissue growth factor fragments and methods and uses thereof |
| AU776150B2 (en) * | 1999-01-28 | 2004-08-26 | Medical College Of Georgia Research Institute, Inc. | Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| US6326193B1 (en) * | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| GB9927444D0 (en) * | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| JP2003526367A (ja) | 2000-03-16 | 2003-09-09 | ジェネティカ インコーポレイテッド | Ｒｎａ干渉の方法とｒｎａ干渉組成物 |
| KR20080023768A (ko) * | 2000-03-30 | 2008-03-14 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체 |
| CN100523215C (zh) | 2000-12-01 | 2009-08-05 | 马普科技促进协会 | 介导rna干涉的小rna分子 |
| JP4779255B2 (ja) | 2001-07-16 | 2011-09-28 | パナソニック株式会社 | レーザ光源 |
| AU2002366641A1 (en) * | 2001-12-11 | 2003-06-23 | Fibrogen, Inc. | Methods for inhibiting ocular processes |
| EP1497420A4 (en) | 2002-04-30 | 2005-04-27 | Alcon Inc | AGENTS THAT REGULATE, RESTRICT OR MODULATE THE ACTIVITY AND / OR EXPRESSION OF BIND WEAVE GROWTH FACTOR (CTGF) AS UNIQUE MEDICAMENTS BOTH TO REDUCE EYESPRINTS AND TREAT GLACCOMPETOSIS RETINOPATHIES / OPTIC NEUROPATHIES |
| CA2524569C (en) * | 2002-05-03 | 2013-10-22 | Duke University | A method of regulating gene expression |
| AU2003261449A1 (en) * | 2002-08-07 | 2004-02-25 | Compositions for rna interference and methods of use thereof | |
| EP1534832A2 (en) | 2002-09-04 | 2005-06-01 | Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin | Compositions and methods for tissue specific or inducible inhibition of gene expression |
| AU2003249012A1 (en) * | 2002-09-30 | 2004-04-23 | Japan As Represented By The President Of The University Of Tokyo | Genes and polypeptides relating to human myeloid leukemia |
| US20040175732A1 (en) * | 2002-11-15 | 2004-09-09 | Rana Tariq M. | Identification of micrornas and their targets |
| JP2007524349A (ja) | 2003-01-16 | 2007-08-30 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | ＩＣＡＭ−１のｓｉＲＮＡ阻害のための組成物及び方法 |
| AU2003224132A1 (en) * | 2003-04-24 | 2004-11-19 | Galapagos Genomics N.V. | Effective sirna knock-down constructs |
| US7462602B2 (en) * | 2003-05-01 | 2008-12-09 | University Of Florida Research Foundation, Inc. | Anti-scarring ribozymes and methods |
| JPWO2004096277A1 (ja) * | 2003-05-01 | 2006-07-13 | 国立大学法人京都大学 | 眼内血管新生疾患の予防又は治療剤 |
| AU2004242586C1 (en) * | 2003-05-28 | 2011-02-24 | Regeneron Pharmaceuticals, Inc. | Method of treating corneal transplant rejection by using VEGF antagonists |
| GB0403600D0 (en) | 2004-02-18 | 2004-03-24 | Trinity College Dublin | Methods and reagents for treating disease |
| GB0404209D0 (en) | 2004-02-25 | 2004-03-31 | Uws Ventures Ltd | Materials and methods for treatment of allergic disease |
-
2005
- 2005-11-24 TW TW094141307A patent/TWI386225B/zh not_active IP Right Cessation
- 2005-12-19 CA CA002591611A patent/CA2591611A1/en not_active Abandoned
- 2005-12-19 EP EP05857141A patent/EP1827503A1/en not_active Withdrawn
- 2005-12-19 MX MX2007007654A patent/MX2007007654A/es active IP Right Grant
- 2005-12-19 AU AU2005319279A patent/AU2005319279B2/en not_active Ceased
- 2005-12-19 KR KR1020077016318A patent/KR20070091337A/ko not_active Ceased
- 2005-12-19 CN CN2005800479231A patent/CN101160138B/zh not_active Expired - Fee Related
- 2005-12-19 US US11/313,200 patent/US7622454B2/en not_active Expired - Fee Related
- 2005-12-19 WO PCT/US2005/046064 patent/WO2006069037A1/en not_active Ceased
- 2005-12-19 EP EP10010890A patent/EP2319543A1/en not_active Withdrawn
- 2005-12-19 JP JP2007548380A patent/JP5095414B2/ja not_active Expired - Fee Related
- 2005-12-19 ZA ZA200704932A patent/ZA200704932B/xx unknown
- 2005-12-19 BR BRPI0516377-3A patent/BRPI0516377A/pt not_active IP Right Cessation
- 2005-12-20 AR ARP050105371A patent/AR052172A1/es unknown
-
2009
- 2009-10-12 US US12/577,267 patent/US7838507B2/en not_active Expired - Fee Related
-
2010
- 2010-10-08 US US12/901,019 patent/US20110028534A1/en not_active Abandoned
-
2012
- 2012-02-14 JP JP2012029499A patent/JP2012097119A/ja not_active Withdrawn
-
2013
- 2013-12-05 US US14/097,928 patent/US20140094502A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6752151B2 (ja) | 遺伝子サイレンシングにおいて低下したｏｆｆ−ｔａｒｇｅｔ効果を有するｕｎａオリゴマー | |
| Drag et al. | Gene therapy for retinal degenerative diseases: progress, challenges, and future directions | |
| JP6924744B2 (ja) | Ｂ型肝炎ウイルスに対する組成物および薬剤ならびにその使用 | |
| ES2563984T3 (es) | Métodos para el tratamiento de trastornos oculares | |
| JP2022501040A5 (enExample) | ||
| JP2022031772A5 (enExample) | ||
| RU2011124528A (ru) | ОПОСРЕДОВАННОЕ PHKI ИНГИБИРОВАНИЕ Rho-КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГЛАЗНЫХ НАРУШЕНИЙ | |
| JP2020158533A (ja) | 眼科症状を処置するまたは予防するための方法 | |
| JP2010501188A5 (enExample) | ||
| RU2008130857A (ru) | Опосредованное phkи ингибирование hif1a для лечения глазного ангиогенеза | |
| RU2007132848A (ru) | Опосредуемое rnai ингибирование мишеней глаза | |
| JP2009540011A5 (enExample) | ||
| BRPI0516377A (pt) | inibição de rnai de ctgf para tratamento de distúrbios oculares | |
| WO2016073918A1 (en) | Methods for treating ocular diseases | |
| RU2008150324A (ru) | Iphk-опосредованное ингибирование связанных с фактором некроза опухоли альфа состояний | |
| JP2012525399A5 (enExample) | ||
| CN108291225A (zh) | 单链反义寡核苷酸在预防或治疗涉及三核苷酸重复扩增的遗传疾病中的用途 | |
| JP2009533475A5 (enExample) | ||
| JP2018521669A (ja) | 治療用オリゴヌクレオチド | |
| JP2022000035A (ja) | ＮＲＡＲＰ遺伝子の発現を阻害するためのｓｉＲＮＡ、並びにそのための方法及び組成物におけるそれらの使用 | |
| JP2025107451A (ja) | 緑内障を治療するためのＷｎｔ５ａの調節 | |
| US20190144865A1 (en) | Modified tgf-beta oligonucleotide for use in a method of preventing and/or treating an ophthalmic disease | |
| JP2009533466A5 (enExample) | ||
| Hussain et al. | The future implications and indications of anti-vascular endothelial growth factor therapy in ophthalmic practice | |
| US10570394B2 (en) | Double-stranded RNA compounds to CASP2 and uses thereof |